Arca's beta-blocker Gencaro receives FDA complete response, further trials requested
This article was originally published in Scrip
Executive Summary
Arca Biopharma has received a US FDA complete response letter for its lead candidate, the beta-blocker Gencaro (bucindolol HCl), which was filed for the treatment of patients with chronic heart failure.